NCT00157534已完成2 期
A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection
BioWest Therapeutics Inc0 个研究点目标入组 43 人开始时间: 2004年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 主要终点
- Safety analysis
研究概览
简要总结
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must be 18 to 65 years of age, inclusive.
- •Primary diagnosis of chronic HCV infection.
排除标准
- •Patients who did not respond or relapsed following therapy with interferon.
结局指标
主要结局
Safety analysis
次要结局
- Hepatitis C viral load
研究者
相似试验
Unknown
2 期
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.Hepatitis BNCT00044135Triangle Pharmaceuticals30
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 InfectionHepatitis C, ChronicNCT00217139BioWest Therapeutics Inc60
已完成
1 期
Celgosivir as a Treatment Against DengueDengue FeverNCT01619969Singapore General Hospital50
已完成
2 期
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseHepatitis C, ChronicNCT02262728Janssen Research & Development, LLC40
已完成
2 期
Safety and Efficacy of Dr. Tagliaferri's Menopause FormulaHot FlashesNCT01957306Herba Buena, Inc30